TuHURA Biosciences, Inc. (NASDAQ: HURA) entered into a $50 million revolving credit facility on April 21 2026, announced the following day. The facility is provided by Parkview Holdings One LLC, an affiliate of the company’s largest stockholder, K&V Investment One LLC. 12% annual interest is charged on outstanding balances, with interest paid monthly and principal due at a five‑year maturity on April 21 2031. The loan is secured by the company’s assets and those of its subsidiaries, giving TuHURA a non‑equity source of capital that can be drawn as needed to fund clinical development and general corporate expenses.
The credit agreement includes a $5 million commitment fee payable in 1.88 million shares, subject to shareholder approval, and extends the exercise period of 4.36 million warrants held by K&V Investment One to 2031. A low‑to‑mid‑single‑digit royalty is payable on net sales of products based on IFx‑2.0, capped at $450 million of annual sales. These terms provide a structured, though costly, financing path that preserves equity while creating a future revenue stream tied to the company’s lead asset.
At the time of the agreement, TuHURA’s cash and cash equivalents were $3.6 million as of December 31 2025, with an additional $7.5 million raised in the first quarter of 2026. The company’s prior cash balance of $2.7 million at September 30 2025 underscores the liquidity pressure that prompted the facility. The new credit line extends the company’s projected cash runway beyond the existing $2.7 million, allowing continued funding of key milestones without further dilution.
The facility is intended to bridge the company through the completion of its Phase 3 registration trial of IFx‑2.0 in advanced or metastatic Merkel cell carcinoma. Updated company guidance indicates enrollment completion is now expected in mid‑2027, rather than the earlier Q4 2026 estimate. The extended timeline means the credit line will support the company through a longer development period, ensuring that clinical and regulatory milestones can be met without compromising operational funding.
Dr. James Bianco, President and CEO, emphasized that the agreement “allows us to fund operations through anticipated key milestones and Phase 3 results of the IFx‑2.0 program while preserving the ability to pursue other capital sources.” He added that the non‑equity nature of the financing and the royalty structure reflect the confidence of the largest shareholder in the company’s strategy and the potential commercial success of IFx‑2.0.
The financing provides a critical lifeline for TuHURA, addressing its negative levered free cash flow and high cash burn. By securing a non‑equity source of capital, the company can maintain momentum in its clinical pipeline while keeping equity dilution to a minimum. The interest and royalty obligations represent a cost of capital that will be offset by future commercial revenues if IFx‑2.0 achieves regulatory approval and market adoption.
revised_sentiment_rating":3}]}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.